Document Type
Article
Abstract
Enterococci are among the leading pathogens isolated in hospital-acquired infections. Current antimicrobial options for vancomycin-resistant enterococci (VRE) are limited. Prior data suggests that daptomycin > 6mg/kg/day may be used to treat enterococcal infections. We retrospectively evaluated the effectiveness and safety of high-dose daptomycin (HD-daptomycin) therapy (> 6 mg/kg) in a multicenter cohort of adult patients with enterococcal infections to describe the characteristics and outcomes. Two-hundred and forty-five patients were evaluated. Enterococcus faecium was identified in 175 (71%), followed by 49 (20%) Enterococcus faecalis and 21 (9%) Enterococcus spp., overall 204 (83%) were VRE. Enterococcal infections included bacteremia (173, 71%), intra-abdominal (35, 14%) and bone/joint (25, 10%). The median dose and duration of HD-daptomycin was 8.2 mg/kg/day (IQR 7.7-9.7) and 10 days (IQR 6-15), respectively. Overall clinical success rate was 89% (193/218) and microbiological eradication was observed in 93% (177/191) of patients. The median time to clearance of blood cultures on HD-daptomycin was 3 days (IQR 2-5). Thirty-day all cause mortality rate was 27% and 5 (2%) patients developed daptomycin nonsusceptible enterococcal strains while on HD-daptomycin. Seven patients (3%) had creatine phosphokinase (CPK) elevation, yet no HD-daptomycin regimen was discontinued due to an elevated CPK and all patients were asymptomatic. Overall, there was a high frequency of clinical success and microbiological eradication in patients treated with HD-daptomycin for enterococcal infections, even in patients with complicated and difficult to treat infections. No adverse event-related discontinuation of HD-daptomycin was noted. HD-daptomycin may be an option for the treatment of enterococcal infections.
Disciplines
Bacterial Infections and Mycoses | Chemicals and Drugs | Hematology | Infectious Disease | Medicine and Health Sciences
Recommended Citation
Casapao et al. Antimicrob. Agents Chemother. September 2013 vol. 57 no. 9 4190-4196
doi:10.1128/AAC.00526-13
Supplementary Table 1
HD Dapto Enterococci Study Manuscript 3-14-13 AAC Format[1].docx (336 kB)
Author's unformatted final accepted manuscript
Included in
Bacterial Infections and Mycoses Commons, Chemicals and Drugs Commons, Hematology Commons, Infectious Disease Commons
Comments
NOTICE IN COMPLIANCE WITH PUBLISHER POLICY: This is the author’s final manuscript version, post-peer-review, of a work accepted for publication in Antimicrobial Agents and Chemotherapy. Changes resulting from the publishing process may not be reflected in this document; changes may have been made to this work since it was submitted for publication. This version has been formatted for archiving; a definitive version was subsequently published in Antimicrobial Agents and Chemotherapy, 57(9): 4190-4196 (September 2013) http://dx.doi.org/10.1128/AAC.00526-13